Pain Management in PICU

← Back to Index (🚑 Emergencies and Critical Care)

Definition and Physiology of Pain

Assessment of Pain in Children

Behavioral and Physiologic Indicators

Pain Assessment Scales

Scale Name Target Age/Population Features & Utility Limitations
Visual Analog Scale (VAS) 6−8 yrs and older Horizontal 10 cm line from "no pain" to "most pain imaginable". Requires cognitive ability to understand proportionality; cannot be used in younger children.
Numerical Rating Scale (NRS) 6−8 yrs and older Integers from 0 to 10. Considered the gold standard for children >8 yrs. Requires numerical processing skills.
Faces Scales (e.g., FACES-R, Wong-Baker) >3 yrs Line drawings or photos of faces indicating progressive distress. Choice of "no pain" face (neutral vs. smiling) affects response; not universally applicable across cultures.
FLACC / Revised FLACC Infants, preverbal, cognitively impaired Assesses
Face,
Legs,
Activity,
Cry, and
Consolability on a 0−2 scale (Total 0−10).
May overrate pain in toddlers and underrate persistent pain.
CRIES Scale Neonates Assesses
Crying,
Requires O2,
Increased vital signs,
Expression, and
Sleeplessness.
Score >4 requires immediate nonpharmacologic and pharmacologic interventions.

Pharmacologic Management

Nonopioid Analgesics (Anti-inflammatory Medications)

Medication Dosage & Administration Comments
Acetaminophen 10−15 mg/kg PO/IV q4h; Max daily: 75 mg/kg/24 hr. No antiplatelet or adverse gastric effects. Overdose causes fulminant hepatic failure.
Ibuprofen 8−10 mg/kg PO q6h; Max daily: 2400 mg. Transient antiplatelet effects; may cause gastritis.
Naproxen 5−7 mg/kg PO q8-12h; Max daily: 1000 mg. Longer duration of action than ibuprofen.
Ketorolac Loading 0.3 mg/kg, then 0.25−0.3 mg/kg IV q6h. Max duration: 5 days. Useful when oral dosing is not feasible. Reversible antiplatelet effects.
Celecoxib ≥2 yrs and 10−25 kg: 50 mg PO bid. COX-2 selective; minimal gastric/antiplatelet effects. Cross-reactive with sulfa allergies.

Opioid Analgesics

Medication Parenteral Dose Oral Dose Comments
Morphine 0.05−0.1 mg/kg q2-4h 0.3 mg/kg q3-4h (immediate release) May cause histamine release and hypotension. Active metabolites excreted renally.
Fentanyl 0.5-1 mcg/kg q1-2h Transmucosal: 10 mcg/kg 70−100 times more potent than morphine. Rapid onset, stable hemodynamics.
Hydromorphone 0.01 mg/kg q2-4h 0.04−0.08 mg/kg q3-4h Five times more potent than morphine. No histamine release.
Methadone 0.1 mg/kg q8-24h 0.1 mg/kg q8-24h Long half-life (15−40 hrs). Useful for chronic pain. Requires monitoring for QTc prolongation.
Oxycodone Not Available 0.1−0.2 mg/kg q3-4h Strong opioid, preferable to hydrocodone.

Local and Topical Anesthetics

Agent Dose / Application Notes
EMLA (Lidocaine 2.5 + Prilocaine 2.5) Dose depends on age/weight (e.g., 1 g for <3 mo). Requires 60 min under occlusive dressing to achieve maximum effect.
LMX4 (Liposomal Lidocaine 5%) 1−20 g depending on age. Requires 30−60 min under occlusive dressing.
LET (Lidocaine, Epinephrine, Tetracaine) Apply to open wounds in children ≥1 yr. Requires 20 min for maximum effect.

Adjuvant and Unconventional Analgesics

Medication Starting Dose Indications & Side Effects
Gabapentin 10−15 mg/kg/day divided bid/tid. Adjunct for neuropathic pain. Side effects: somnolence, dizziness.
Pregabalin 2.5 mg/kg/day divided bid/tid. Neuropathic pain, fibromyalgia. Side effects: ataxia, weight gain, drowsiness.
Amitriptyline / Nortriptyline 0.1 mg/kg PO qhs (for 25−50 kg). Neuropathic pain, migraines. Side effects: sedation, dry mouth, prolonged QTc.
Clonidine 5−25mcg/kg/day divided q4-8h. Anxiolytic, manages opioid withdrawal, neuropathic pain. Side effects: hypotension, bradycardia.
Ketamine Loading 0.25−0.5 mg/kg IV. NMDA receptor antagonist. Excellent for opioid-tolerant patients. Side effects: hallucinations, excess secretions.

Non-Pharmacologic Management

Modalities by Age

Cognitive-Behavioral Therapy (CBT)

Management in Specific Clinical Scenarios

Procedural Sedation and Analgesia

Burn Pain Management

Cancer and Palliative Care